<bill session="115" type="h" number="6958" updated="2019-04-18T16:27:52Z">
  <state datetime="2018-09-27">REFERRED</state>
  <status>
    <introduced datetime="2018-09-27"/>
  </status>
  <introduced datetime="2018-09-27"/>
  <titles>
    <title type="official" as="introduced">To provide for a study and report on the feasibility of basing reimbursement rates for Medicare part B drugs and covered part D drugs on the average prices for such drugs in the member-states of the Organization for Economic Cooperation and Development.</title>
    <title type="short" as="introduced">Drug Price Transparency Act</title>
    <title type="short" as="introduced">Drug Price Transparency Act</title>
    <title type="display">Drug Price Transparency Act</title>
  </titles>
  <sponsor bioguide_id="R000607"/>
  <cosponsors>
    <cosponsor bioguide_id="W000800" joined="2018-09-27"/>
  </cosponsors>
  <actions>
    <action datetime="2018-09-27">
      <text>Introduced in House</text>
    </action>
    <action datetime="2018-09-27" state="REFERRED">
      <text>Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.</text>
    </action>
    <action datetime="2018-09-27">
      <text>Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.</text>
    </action>
    <action datetime="2018-10-10">
      <text>Referred to the Subcommittee on Health.</text>
    </action>
  </actions>
  <committees>
    <committee subcommittee="" code="HSWM" name="House Ways and Means" activity="Referral"/>
    <committee subcommittee="Health" code="HSWM02" name="House Ways and Means" activity="Referral"/>
    <committee subcommittee="" code="HSIF" name="House Energy and Commerce" activity="Referral"/>
  </committees>
  <relatedbills/>
  <subjects>
    <term name="Health"/>
    <term name="Congressional oversight"/>
    <term name="Government studies and investigations"/>
    <term name="Health care costs and insurance"/>
    <term name="Inflation and prices"/>
    <term name="International organizations and cooperation"/>
    <term name="Medicare"/>
    <term name="Prescription drugs"/>
  </subjects>
  <amendments/>
  <summary date="2018-09-27T04:00:00Z" status="Introduced in House">Drug Price Transparency Act

This bill requires the Centers for Medicare &amp; Medicaid Services to report on the feasibility of basing payment rates for prescription drugs under Medicare and Medicare Advantage on the average price of such drugs in countries that are members of the Organization for Economic Cooperation and Development (an intergovernmental organization focused on global economic development).</summary>
  <committee-reports/>
</bill>
